Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $400.0 million.

  • Pharming Group N.V's Liabilities and Shareholders Equity rose 11.34% to $473.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 1.30%. This contributed to the annual value of $400.0 million for FY2024, which is 13.58% down from last year.
  • Per Pharming Group N.V's latest filing, its Liabilities and Shareholders Equity stood at $400.0 million for FY2024, which was down 13.58% from $462.9 million recorded in FY2023.
  • Pharming Group N.V's 5-year Liabilities and Shareholders Equity high stood at $462.9 million for FY2023, and its period low was $418,453 during FY2020.
  • Over the past 3 years, Pharming Group N.V's median Liabilities and Shareholders Equity value was $425.8 million (recorded in 2022), while the average stood at $429.5 million.
  • Per our database at Business Quant, Pharming Group N.V's Liabilities and Shareholders Equity slumped by 99.84% in 2020 and then soared by 94,848.54% in 2021.
  • Over the past 5 years, Pharming Group N.V's Liabilities and Shareholders Equity (Yearly) stood at $418,453 in 2020, then soared by 94,848.54% to $397.3 million in 2021, then increased by 7.17% to $425.8 million in 2022, then increased by 8.70% to $462.9 million in 2023, then declined by 13.58% to $400.0 million in 2024.